Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific's regulatory disclosures and financial reporting.
Core Scientific, Inc. reported that officer Todd M. Duchene sold a total of 10,000 shares of common stock in the open market on June 8, 2026. The sales occurred in two blocks: 4,500 shares at a weighted average price of $27.1053 per share and 5,500 shares at a weighted average price of $26.6376 per share.
The filing notes that these transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on December 5, 2025, meaning the trades were pre-arranged rather than timed at the officer’s discretion.
Core Scientific, Inc. reported that officer Todd M. Duchene sold a total of 10,000 shares of common stock in the open market on June 8, 2026. The sales occurred in two blocks: 4,500 shares at a weighted average price of $27.1053 per share and 5,500 shares at a weighted average price of $26.6376 per share.
The filing notes that these transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on December 5, 2025, meaning the trades were pre-arranged rather than timed at the officer’s discretion.
Core Scientific, Inc. officer Todd M. Duchene reported selling a total of 10,000 shares of Common Stock on June 1, 2026 in open-market transactions. The sales were executed in three blocks at weighted average prices of $26.9285, $28.2666, and $28.7561 per share.
The filing notes these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Footnotes explain that each reported price is a weighted average for multiple individual trades within price ranges from $26.54 to $28.97.
Core Scientific, Inc. officer Todd M. Duchene reported selling a total of 10,000 shares of Common Stock on June 1, 2026 in open-market transactions. The sales were executed in three blocks at weighted average prices of $26.9285, $28.2666, and $28.7561 per share.
The filing notes these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Footnotes explain that each reported price is a weighted average for multiple individual trades within price ranges from $26.54 to $28.97.
Smith Stephen M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific director Stephen M. Smith received a grant of 18,961 shares of Common Stock in the form of restricted stock units. The RSUs were granted at no cash cost and will vest in two substantially equal installments on May 26, 2027 and May 26, 2028, contingent on his continued service.
Smith Stephen M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific director Stephen M. Smith received a grant of 18,961 shares of Common Stock in the form of restricted stock units. The RSUs were granted at no cash cost and will vest in two substantially equal installments on May 26, 2027 and May 26, 2028, contingent on his continued service.
Core Scientific, Inc. director Stephen M. Smith filed an initial ownership report on Form 3. This filing identifies him as a director of the company but does not list any specific share or option holdings or transactions at this time.
Core Scientific, Inc. director Stephen M. Smith filed an initial ownership report on Form 3. This filing identifies him as a director of the company but does not list any specific share or option holdings or transactions at this time.
Core Scientific, Inc. officer Todd M. Duchene reported an open-market sale of 10,000 shares of Common Stock on May 26, 2026 at a weighted average price of $26.254 per share. The transactions were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were pre-scheduled. After these sales, Duchene directly holds 2,088,895 shares, so the sale represents a relatively small portion of his overall position. The shares were sold in multiple trades at prices ranging from $25.81 to $26.75.
Core Scientific, Inc. officer Todd M. Duchene reported an open-market sale of 10,000 shares of Common Stock on May 26, 2026 at a weighted average price of $26.254 per share. The transactions were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were pre-scheduled. After these sales, Duchene directly holds 2,088,895 shares, so the sale represents a relatively small portion of his overall position. The shares were sold in multiple trades at prices ranging from $25.81 to $26.75.
Jane Street Group, LLC reports beneficial ownership of 23,967,780 shares of Core Scientific, Inc./tx common stock, representing 7.5% of the class. The filing identifies subsidiary holdings: Jane Street Capital, LLC (20,703,298 shares; 6.5%) and Jane Street Global Trading, LLC (3,264,482 shares; 1.0%). The statement shows shared voting and shared dispositive power over the 23,967,780 shares and is signed by Jeremy Kahn as authorized signatory.
Jane Street Group, LLC reports beneficial ownership of 23,967,780 shares of Core Scientific, Inc./tx common stock, representing 7.5% of the class. The filing identifies subsidiary holdings: Jane Street Capital, LLC (20,703,298 shares; 6.5%) and Jane Street Global Trading, LLC (3,264,482 shares; 1.0%). The statement shows shared voting and shared dispositive power over the 23,967,780 shares and is signed by Jeremy Kahn as authorized signatory.
Core Scientific, Inc. appointed Steve M. Smith to its Board of Directors and its Nominating and Corporate Governance Committee, effective immediately. The company describes itself as a leader in digital infrastructure for high-density colocation serving AI-related workloads.
Smith, age 70, is currently Chief Executive Officer of Zayo Group and previously served as CEO and President of Equinix from 2007 to 2018, where he helped grow annual revenue from about $400 million to more than $4 billion and integrated over 20 acquisitions. The Board has determined he is independent under Sarbanes-Oxley and Nasdaq rules, and he will receive cash and equity compensation consistent with other non-employee directors. There are no family relationships or related-party transactions disclosed. Core Scientific notes that its majority revenue comes from high-density colocation services as it repurposes remaining mining facilities to support this business.
Core Scientific, Inc. appointed Steve M. Smith to its Board of Directors and its Nominating and Corporate Governance Committee, effective immediately. The company describes itself as a leader in digital infrastructure for high-density colocation serving AI-related workloads.
Smith, age 70, is currently Chief Executive Officer of Zayo Group and previously served as CEO and President of Equinix from 2007 to 2018, where he helped grow annual revenue from about $400 million to more than $4 billion and integrated over 20 acquisitions. The Board has determined he is independent under Sarbanes-Oxley and Nasdaq rules, and he will receive cash and equity compensation consistent with other non-employee directors. There are no family relationships or related-party transactions disclosed. Core Scientific notes that its majority revenue comes from high-density colocation services as it repurposes remaining mining facilities to support this business.
Nygaard James P Jr reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. executive vice president and chief financial officer James P. Nygaard Jr. reported receiving a grant of 120,074 shares of Common Stock in the form of restricted stock units as equity compensation.
According to the filing, one-third of these RSUs will vest on March 15, 2027, and the remaining two-thirds will vest in eight substantially equal quarterly installments after that date, as long as he continues providing service to the company on each vesting date. Following this award, he holds 1,043,056 shares of Common Stock directly.
Nygaard James P Jr reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. executive vice president and chief financial officer James P. Nygaard Jr. reported receiving a grant of 120,074 shares of Common Stock in the form of restricted stock units as equity compensation.
According to the filing, one-third of these RSUs will vest on March 15, 2027, and the remaining two-thirds will vest in eight substantially equal quarterly installments after that date, as long as he continues providing service to the company on each vesting date. Following this award, he holds 1,043,056 shares of Common Stock directly.
DUCHENE TODD M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that officer Todd M. Duchene received an annual grant of 138,547 shares of common stock in the form of restricted stock units on May 20, 2026, at no purchase price. One-third of these RSUs will vest on March 15, 2027, with the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter, as long as he continues serving the company on each vesting date. Following this equity award, Duchene directly holds 2,098,895 shares of Core Scientific common stock.
DUCHENE TODD M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that officer Todd M. Duchene received an annual grant of 138,547 shares of common stock in the form of restricted stock units on May 20, 2026, at no purchase price. One-third of these RSUs will vest on March 15, 2027, with the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter, as long as he continues serving the company on each vesting date. Following this equity award, Duchene directly holds 2,098,895 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.